Psychedelics and Neuroplasticity in Cognitive Aging
Current understanding
Psilocybin and related serotonergic psychedelics are hypothesized to transiently open windows of heightened neuroplasticity via 5-HT2A signaling, dendritic spine growth, and BDNF pathways (mechanism-plausible). An early registered trial is testing intermittent oral psilocybin paired with cognitive training in adults 65+ spanning normal cognition, MCI, and early Alzheimer’s, against cognitive training alone (mechanism-plausible; protocol-stage, no efficacy readout). No outcome-level human evidence yet supports psychedelic-assisted cognitive rehabilitation in aging populations.
Evidence log
- 2026-11-11 — Lysergic Acid Diethylamide Induces Transcriptional Changes Opposing Signatures of Brain Ageing and Neurodegeneration: [mechanism-plausible] A preclinical transcriptomic study reports LSD-induced brain gene-expression profiles opposing signatures of aging and neurodegeneration, providing molecular rationale rather than evidence of improved cognition, reduced dementia risk, or extended healthspan. [mechanism-plausible] (novelty: 3)
- 2026-08-17 — Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life: LONG-LIFE Phase I trial registered to test 1–3 doses of 25 mg psilocybin vs wait-list on aging biomarkers, cognition, and purpose in life in medically stable adults 60–80; protocol-stage dose-ranging launch, no efficacy or biomarker readout yet. [mechanism-plausible] (novelty: 4)